Alnylam Pharma (ALNY) Tops Q2 EPS by 19c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $321.59 +2.73%
EPS Growth %: +403.1%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +403.1%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.05), $0.19 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $8.09 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- UBS Reiterates Buy Rating on Smurfit Westrock (SW)
- Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
